Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency

Irina Petrache, Joud Hajjar, Michael Campos, Irina Petrache, Joud Hajjar, Michael Campos

Abstract

Alpha-1-antitrypsin deficiency (AATD), also known as alpha1-proteinase inhibitor deficiency, is an autosomal co-dominant condition. The genotypes associated with AATD include null, deficient, and dysfunctional alpha-1-antitrypsin (A1AT) variants, which result in low levels of circulating functional A1AT, unbalanced protease activity, and an increased risk of developing lung emphysema, the leading cause of morbidity in these patients. Furthermore, the most common abnormal genotype, Pi*ZZ may also cause trapping of abnormally folded protein polymers in hepatocytes causing liver dysfunction. A major focus of therapy for patients with lung disease due to AATD is to correct the A1AT deficiency state by augmenting serum levels with intravenous infusions of human plasma-derived A1AT. This strategy has been associated with effective elevations of A1AT levels and function in serum and lung epithelial fluid and observational studies suggest that it may lead to attenuation in lung function decline, particularly in patients with moderate impairment of lung function. In addition, an observational study suggests that augmentation therapy is associated with a reduction of mortality in subjects with AATD and moderate to severe lung impairment. More recent randomized placebo-controlled studies utilizing computer scan densitometry suggest that this therapy attenuates lung tissue loss. Augmentation therapy has a relative paucity of side effects, but it is highly expensive. Therefore, this therapy is recommended for patients with AATD who have a high-risk A1AT genotype with plasma A1AT below protective levels (11 microM) and evidence of obstructive lung disease. In this article, we review the published evidence of A1AT augmentation therapy efficacy, side effects, and safety profile.

Keywords: COPD; alpha-1 antitrypsin; intravenous augmentation therapy.

References

    1. Perlmutter DH, Joslin G, Nelson P, et al. Endocytosis and degradation of alpha 1-antitrypsin-protease complexes is mediated by the serpin-enzyme complex (SEC) receptor. J Biol Chem. 1990;265(28):16713–16716.
    1. Sveger T. alpha 1-antitrypsin deficiency in early childhood. Pediatrics. 1978;62(1):22–25.
    1. Hutchison DC. Alpha 1-antitrypsin deficiency in Europe: geographical distribution of Pi types S and Z. Respir Med. 1998;92(3):367–377.
    1. O’Brien ML, Buist NR, Murphey WH. Neonatal screening for alpha1-antitrypsin deficiency. J Pediatr. 1978;92(6):1006–1010.
    1. Silverman EK, Miletich JP, Pierce JA, et al. Alpha1-antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis. 1989;140(4):961–966.
    1. Okayama H, Brantly M, Holmes M, et al. Characterization of the molecular basis of the alpha 1-antitrypsin F allele. Am J Hum Genet. 1991;48(6):1154–1158.
    1. Taggart C, Cervantes-Laurean D, Kim G, et al. Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem. 2000;275(35):27258–27265.
    1. Mulgrew AT, Taggart CC, Lawless MW, et al. Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest. 2004;125(5):1952–1957.
    1. Mahadeva R, Atkinson C, Li Z, et al. Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol. 2005;166(2):377–386.
    1. Geraghty P, Rogan MP, Greene CM, et al. Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix met alloprotease 2 in vivo and in vitro. Thorax. 2008;63(7):621–626.
    1. Taggart CC, Lowe GJ, Greene CM, et al. Cathepsin BL, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem. 2001;276(36):33345–33352.
    1. Petrache I, Fijalkowska I, Medler TR, et al. {alpha}-1 Antitrypsin Inhibits Caspase-3 Activity, Preventing Lung Endothelial Cell Apoptosis. Am J Pathol. 2006;169(4):1155–1166.
    1. Petrache I, Fijalkowska I, Zhen L, et al. A Novel Anti-apoptotic Role for Alpha-1 Antitrypsin in the Prevention of Pulmonary Emphysema. Am J Respir Crit Care Med. 2006;173(11):1222–1228.
    1. Ikebe N, Akaike T, Miyamoto Y, et al. Protective effect of S-nitrosylated alpha(1)-protease inhibitor on hepatic ischemia-reperfusion injury. J Pharmacol Exp Ther. 2000;295(3):904–911.
    1. Baranger K, Zani ML, Chandenier J, et al. The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function. FEBS J. 2008;275(9):2008–2020.
    1. Doumas S, Kolokotronis A, Stefanopoulos P. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun. 2005;73(3):1271–1274.
    1. Williams SE, Brown TI, Roghanian A, et al. SLPI and elafin: one glove, many fingers. Clin Sci (Lond) 2006;110(1):21–35.
    1. Tuder RM, Petrache I. Molecular multitasking in the airspace: alpha1-antitrypsin takes on thrombin and plasmin. Am J Respir Cell Mol Biol. 2007;37(2):130–134.
    1. Aldonyte R, Hutchinson ET, Jin B, et al. Endothelial alpha-1-antitrypsin attenuates cigarette smoke induced apoptosis in vitro. COPD. 2008;5(3):153–162.
    1. Churg A, Wang X, Wang RD, et al. Alpha1-antitrypsin suppresses TNF-alpha and MMP-12 production by cigarette smoke-stimulated macrophages. Am J Respir Cell Mol Biol. 2007;37(2):144–151.
    1. Nita I, Hollander C, Westin U, et al. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release. Respir Res. 2005;6:12.
    1. Subramaniyam D, Virtala R, Pawlowski K, et al. TNF-alpha-induced self expression in human lung endothelial cells is inhibited by native and oxidized alpha1-antitrypsin. Int J Biochem Cell Biol. 2008;40(2):258–271.
    1. Lazrak A, Nita I, Subramaniyam D, et al. Alpha1-antitrypsin inhibits epithelial Na+ transport in vitro and in vivo. Am J Respir Cell Mol Biol. 2009 Jan 8; [Epub ahead of print]
    1. Swystun V, Chen L, Factor P, et al. Apical trypsin increases ion transport and resistance by a phospholipase C-dependent rise of Ca2+ Am J Physiol Lung Cell Mol Physiol. 2005;288(5):L820–30.
    1. Mahadeva R, Chang WS, Dafforn TR, et al. Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis. J Clin Invest. 1999;103(7):999–1006.
    1. Perlmutter DH. Autophagic disposal of the aggregation-prone protein that causes liver inflammation and carcinogenesis in alpha-1-antitrypsin deficiency. Cell Death Differ. 2009;16(1):39–45.
    1. Ranes J, Stoller JK. A review of alpha-1 antitrypsin deficiency. Semin Respir Crit Care Med. 2005;26(2):154–166.
    1. Campos MA, Alazemi S, Zhang G, et al. Clinical characteristics of subjects with symptoms of alpha1-antitrypsin deficiency older than 60 years. Chest. 2009;135(3):600–608.
    1. American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900.
    1. Nowack R, Flores-Suarez LF, van der Woude FJ. New developments in pathogenesis of systemic vasculitis. Curr Opin Rheumatol. 1998;10(1):3–11.
    1. Valverde R, Rosales B, Ortiz-de Frutos FJ, et al. Alpha-1-antitrypsin deficiency panniculitis. Dermatol Clin. 2008;26(4):447–451. vi.
    1. Wilcke JT, Dirksen A. The effect of inhaled glucocorticosteroids in emphysema due to alpha1-antitrypsin deficiency. Respir Med. 1997;91(5):275–279.
    1. Campos MA, Alazemi S, Zhang G, et al. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD. 2009;6(1):31–40.
    1. Spencer LT, Humphries JE, Brantly ML. Antibody response to aerosolized transgenic human alpha1-antitrypsin. N Engl J Med. 2005;352(19):2030–2031.
    1. McLean C GC, McElvaney NG. Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency. Biologics: Targets and Therapy. 2009;3:63–75.
    1. Wewers MD, Gadek JE, Keogh BA, et al. Evaluation of danazol therapy for patients with PiZZ alpha-1-antitrypsin deficiency. Am Rev Respir Dis. 1986;134(3):476–480.
    1. Wewers MD, Brantly ML, Casolaro MA, et al. Evaluation of tamoxifen as a therapy to augment alpha-1-antitrypsin concentrations in Z homozygous alpha-1-antitrypsin-deficient subjects. Am Rev Respir Dis. 1987;135(2):401–402.
    1. Seersholm N, Wencker M, Banik N, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997;10(10):2260–2263.
    1. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316(17):1055–1062.
    1. Gadek JE, Klein HG, Holland PV, et al. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest. 1981;68(5):1158–1165.
    1. Gottlieb DJ, Luisetti M, Stone PJ, et al. Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group. Am J Respir Crit Care Med. 2000;162(6):2069–2072.
    1. Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin. Chest. 2002;122(1):66–74.
    1. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 1998;158(1):49–59.
    1. Wencker M, Fuhrmann B, Banik N, et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 2001;119(3):737–744.
    1. Chapman KR, Bradi AC, Paterson D, et al. Slower lung function decline during augmentation therapy in patients with alpha-1 antitrypsin deficiency: results from the Canadian AIR Registry. Proc Am Thorac Soc. 2005;2:A808.
    1. Schluchter MD, Stoller JK, Barker AF, et al. Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 2000;161(3 Pt 1):796–801.
    1. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416–469.
    1. Stolk J, Putter H, Bakker EM, et al. Progression parameters for emphysema: a clinical investigation. Respir Med. 2007;101(9):1924–1930.
    1. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1468–1472.
    1. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha-1 antitrypsin deficiency. Eur Respir J. 2009 Feb 5; [Epub ahead of print]
    1. Stockley RA, Bayley DL, Unsal I, et al. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002;165(11):1494–1498.
    1. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest. 2000;118(5):1480–1485.
    1. Needham M, Stockley RA. Exacerbations in {alpha}1-antitrypsin deficiency. Eur Respir J. 2005;25(6):992–1000.
    1. Campos MA, Sandhaus R. Exacerbations of respiratory symptoms in patients with alpha-1 antitrypsin deficiency on augmentation therapy. Am J Respir Crit Care Med. 2004;169(7):A767.
    1. Griesenbach U, Chonn A, Cassady R, et al. Comparison between intratracheal and intravenous administration of liposome-DNA complexes for cystic fibrosis lung gene therapy. Gene Ther. 1998;5(2):181–188.
    1. Hubbard RC, Sellers S, Czerski D, et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA. 1988;260(9):1259–1264.
    1. Barker AF, Iwata-Morgan I, Oveson L, et al. Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency. Chest. 1997;112(3):607–613.
    1. Piitulainen E, Bernspang E, Bjorkman S, et al. Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin. Eur J Clin Pharmacol. 2003;59(2):151–156.
    1. Soy D, de la Roza C, Lara B, et al. Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Thorax. 2006;61(12):1059–1064.
    1. Zamora NP, Pla RV, Del Rio PG, et al. Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy. Ann Pharmacother. 2008;42(5):640–646.
    1. Dahl M, Tybjaerg-Hansen A, Lange P, et al. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: A longitudinal study of the general population. Ann Intern Med. 2002;136(4):270–279.
    1. Hersh CP, Dahl M, Ly NP, et al. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax. 2004;59(10):843–849.
    1. Sandhaus RA, Turino G, Stocks J, et al. alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note. Chest. 2008;134(4):831–834.
    1. Wencker M, Banik N, Buhl R, et al. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J. 1998;11(2):428–433.
    1. Stoller JK, Fallat R, Schluchter MD, et al. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest. 2003;123(5):1425–1434.
    1. Meyer FJ, Wencker M, Teschler H, et al. Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor. Eur Respir J. 1998;12(4):996–997.
    1. Stocks JM, Brantly M, Pollock D, et al. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. COPD. 2006;3(1):17–23.
    1. Cowden DI, Fisher GE, Weeks RL. A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) products. Curr Med Res Opin. 2005;21(6):877–883.
    1. Mullins CD, Wang J, Stoller JK. Major components of the direct medical costs of alpha1-antitrypsin deficiency. Chest. 2003;124(3):826–831.
    1. Mullins CD, Huang X, Merchant S, et al. The direct medical costs of alpha(1)-antitrypsin deficiency. Chest. 2001;119(3):745–752.
    1. Hay JW, Robin ED. Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. Am J Public Health. 1991;81(4):427–433.
    1. Alkins SA, O’Malley P. Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis. Chest. 2000;117(3):875–880.
    1. Gildea TR, Shermock KM, Singer ME, et al. Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2003;167(10):1387–1392.
    1. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67–74.
    1. Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung. 1990;168 (Suppl):565–578.
    1. Vogelmeier C, Kirlath I, Warrington S, et al. The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers. Am J Respir Crit Care Med. 1997;155(2):536–541.
    1. King MB, Campbell EJ, Gray BH, et al. The proteinase-antiproteinase balance in alpha-1-proteinase inhibitor-deficient lung transplant recipients. Am J Respir Crit Care Med. 1994;149(4 Pt 1):966–971.
    1. Trulock EP. Lung transplantation for alpha 1-antitrypsin deficiency emphysema. Chest. 1996;110(6 Suppl):284S–294S.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться